Generation of an inducible and optimized piggyBac transposon system. by Cadiñanos, Juan & Bradley, Allan
Published online 18 June 2007 Nucleic Acids Research, 2007, Vol. 35, No. 12 e87
doi:10.1093/nar/gkm446
Generation of an inducible and optimized piggyBac
transposon systemy
Juan Cadin˜anos and Allan Bradley*
The Wellcome Trust Sanger Institute. Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK
Received March 22, 2007; Revised May 14, 2007; Accepted May 18, 2007
ABSTRACT
Genomic studies in the mouse have been slowed by
the lack of transposon-mediated mutagenesis.
However, since the resurrection of Sleeping Beauty
(SB), the possibility of performing forward genetics
in mice has been reinforced. Recently, piggyBac
(PB), a functional transposon from insects, was also
described to work in mammals. As the activity of PB
is higher than that of SB11 and SB12, two hyper-
active SB transposases, we have characterized and
improved the PB system in mouse ES cells. We have
generated a mouse codon-optimized version of the
PB transposase coding sequence (CDS) which
provides transposition levels greater than the
original. We have also found that the promoter
sequence predicted in the 50-terminal repeat of the
PB transposon is active in the mammalian context.
Finally, we have engineered inducible versions of the
optimized piggyBac transposase fused with ERT2.
One of them, when induced, provides higher levels of
transposition than the native piggyBac CDS,
whereas in the absence of induction its activity is
indistinguishable from background. We expect that
these tools, adaptable to perform mouse-germline
mutagenesis, will facilitate the identification of
genes involved in pathological and physiological
processes, such as cancer or ES cell differentiation.
INTRODUCTION
Forward genetics, where the observation of a phenotype is
followed by the identification of the responsible gene(s),
provides a valuable tool to carry out functional genomics.
The availability of systems to generate tagged mutations
on a large scale facilitates this kind of approach,
permitting the production of collections of genetically
modified cells or organisms which can then be phenotyp-
ically screened (1). The molecular label conferred by the
tagging mutagen allows for a ready identification of the
locus responsible for the observed phenotype. Due to their
ability to mobilize around genomes, DNA transposons
and retrotransposons have been widely used as tools to
generate mutation libraries in a variety of organisms.
DNA transposons are genetic elements consisting of
inverted terminal DNA repeats (TRs) which in their
naturally occurring configuration flank a transposase
coding sequence (CDS). This transposase follows a ‘cut
and paste’ mechanism to excise the transposon from its
original genomic location and insert it into a new
locus (2). Retrotransposons, however, use an RNA
intermediary molecule and retrotranscription to ‘copy
and paste’ themselves in different locations of the genome.
In mammals, the lack of efficient transposon systems has
largely precluded the application of this type of mutagen-
esis. However, the awakening of the use of DNA
transposons and the recent success with synthetic retro-
transposons in the mouse is opening wide the door of
forward genetics in this model organism (3,4).
In 1997, Ivics et al. resurrected a Tc1-like DNA
transposon by comparing the nucleotide sequences of
a number of dormant inactive elements in salmonid
fishes, predicting the active sequence and repairing the
inactivating mutations. This elegant and meticulous
approach resulted in an active transposon termed
Sleeping Beauty (SB). The SB system was soon reported
to be functional in human and murine cells (3,5,6).
Moreover, since its resurrection, both the inverted repeats
and the transposase coding sequence have been optimized,
which has yielded an SB element with increased mobiliza-
tion activity (7–11). This has been used in mammals for a
wide range of applications, such as gene therapy, germline
mutagenesis and somatic mutagenesis (8,12–15).
The activity of the system needs to be regulated, because
excessive and uncontrolled transposition results in genomic
instability such as inversions, deletions and translocations
(14). These large-scale genomic rearrangements mask
the more subtle and informative singular transposition
events, interfering with the identification of single genes
responsible for specific phenotypes. Thus, the availability
of a highly active, though regulatable, transposase would
be desirable.
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In addition to SB, piggyBac (PB), a transposable
element originally isolated from the genome of the
cabbage looper moth Trichoplusia ni has also been
reported to be highly active when introduced into
mammalian genomes, including human (16–18) and
mouse cells (16). In a direct comparison experiment
involving in vitro transfection, PB has been reported to
be the most active of four tested transposons, including
PB, SB11 (one of the hyperactive SB transposases), Tol2
and Mos1 (17). In a separate study, PB has also been
shown to be more active than SB12, another hyperactive
version of SB (18). Although there are other hyperactive
SB transposases available, which apparently show higher
activity than SB11 and SB12, they have not been directly
compared to PB (19,20). Given its good performance
in mammals we have characterized and optimized the
PB system for its utilization in mouse ES cells and for
somatic mutagenesis in vivo. We have generated a mouse
codon-optimized version of the PB transposase CDS and
we have observed that it provides levels of transposition
considerably higher than those of the native PB CDS.
We have analysed the differential properties of the 50 and
30-terminal repeats of the PB transposon, uncovering the
existence of promoter activity in the 50-terminal repeat.
Finally, we have created a highly active and regulatable
PB transposase, by fusing the optimized PB CDS to the
modified ligand-binding domain of the oestrogen receptor,
ERT2. We expect that this optimized transposon system
will significantly expand the utility of transposon-based
mutagenesis for the genetic characterization of the mouse
genome.
MATERIALS AND METHODS
Plasmids
iPB and mPB were custom synthesized. Besides the PB
transposase CDS, both sequences included a Kozak
element around the start ATG at the 50-end and two
consecutive stop codons at the 30-end. EcoRI and NotI
flank the 50 and 30-ends, respectively, and they were used
to clone both CDSs into pcDNA3 or pcDNA3-KzHA. To
produce the donor plasmids, the puroDTK fusion gene and
the bovine growth hormone polyA signal were PCR
amplified from pFlexible (21). En2SA was PCR amplified
from T2/Onc, kindly provided by Dr L. Collier, and the
EMCV IRES sequence was sub-cloned from pPRIG,
which was a gift by Dr P. Martin (12,22). The minimal 50
and 30-PB terminal repeats were custom synthesized and
then combined by sub-cloning to produce the desired
configurations. The Luc2 sequence corresponds to a
HindIII/BamHI fragment from pGL4.13 (Promega).
ERT2 was PCR amplified from a cDNA kindly provided
by Dr P. Chambon and subcloned at the 50 or at the 30 of
mPB. L1 linkers were created as a result of the cloning
process. L2 and L3 linkers were introduced between mPB
and ERT2 by sub-cloning the pairs of primers shown in
Supplementary Table 1. The core aminoacidic sequence of
the L3 linker was kindly provided by Dr Joseph Kaminski.
The CDSs and protein sequences of mPB (GenBank
accession number: EF587698) and mPB-L3-ERT2
(GenBank accession number: EF587699) are shown in
Supplementary Figure 1.
Cell culture and transfection
AB2.2 ES cells were cultured on a layer of mitotically
inactive SNL76/7 feeder cells and transfected by electro-
poration as described previously (23). Puromycin selection
was conducted on SNLP 76/7-4 feeders (a puromycin
resistant derivative of SNL76/7) with 3 mg/ml of puromy-
cin. Puromycin resistant ES cell colonies were stained for
15min with 1% methylene blue in 70% EtOH, washed in
distilled water over night and air-dried. This protocol
produced a very low background which allowed counting
colonies with diameters >0.3mm. COS-7 cells and
HeLaS3 cells were grown in 6-well plates and with
DMEM supplemented with 10% foetal bovine serum.
Plasmids were transfected with Lipofectamine 2000
(Invitrogen), following manufacturer’s instructions.
Western blot
Transfected COS-7 cells were washed with PBS and
each well was harvested with 500 ml 2Laemmli buffer.
Fifteen microlitres of lysate were loaded per lane in a
4–12% gradient SDS–PAGE gel (Invitrogen). The gel was
transferred to a Hybond-ECLTM (Amersham Biosciences)
membrane, and the membrane was dried over night
and blocked with 5% non-fat dry milk dissolved in PT
(0.1% Tween-20 in 1 PBS) for 1 h at room temperature.
Table 1. Sequences and properties of the linkers used in the fusion PB transposases engineered in this work
Version Nt Linker Ct pI Charge
ERT2-L1-mPB . . .PATA- -CEFAAT- -MGSS. . . 4 
mPB-L1-ERT2 . . .QSCF- -AAA- -SAGD. . . 5.57 
ERT2-L2-mPB . . .PATA- -CELSLGAAPDAAPGSEFAAT- -MGSS. . . 3.57 
mPB-L2-ERT2 . . .QSCF- -AAASLGAAPDAAPGSGAA- -SAGD. . . 3.8 
ERT2-L3-mPB . . .PATA- -CEFKAKLGGGAPAVGGGPKAADKFAAT- -MGSS. . . 9.05 +
mPB-L3-ERT2 . . .QSCF- -AAAKLGGGAPAVGGGPKAADKGAA- -SAGD. . . 9.53 +
Columns from left to right: ‘Version’ indicates the different fusion transposases. ‘Nt’ indicates the aminoacidic sequence of the N-terminal half of the
fusion protein immediately proximal to the linker. ‘Linker’ corresponds to the sequence of aminoacids between both halves of fusion protein. Bold
aminoacids highlight the core linker sequences. ‘Ct’ indicates the aminoacidic sequence of the C-terminal half of the fusion protein immediately
proximal to the linker. ‘pI’ corresponds to the isoelectric point of the linker. ‘Charge’ indicates the predicted sign of the net electric charge of the
linker at intracellular pH conditions.
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Then, it was incubated with 12CA5 anti-HA monoclonal
antibody (Abcam, cat #ab16918) or with anti-actin
monoclonal antibody (Sigma, cat #A5316), both diluted
1:1000 in 3% non-fat milk dissolved in PT for 1 h at room
temperature. The membrane was washed 3 times for 5min
with PT and incubated with the peroxidase-labelled
anti-mouse antibody from the ECLTM Western Blot
Analysis System (GE Healthcare) diluted 1/10000 in
1.5% non-fat dry milk for 1 h at room temperature. The
membrane was washed again as before and specific protein
bands were detected using ECLTM Western Blot Analysis
System (GE Healthcare).
Luciferase assay
Transfected HeLaS3 cells were washed with PBS and each
well was lysed for 15min with 100 ml of 1 passive lysis
buffer from the Dual Luciferase Reporter Assay System
(Promega). Lysates were harvested and 20 ml of each
sample were analysed for luciferase activity following the
manufacture’s instructions in a MicroLumatPlus LB 96V
luminometer (Berthold Technologies).
RESULTS
Increased transposition by codon-optimization of PB
transposase
As the PB transposon was originally isolated from insect
cells, we hypothesized that a mouse codon-optimization of
the transposase CDS might produce higher levels of
transposition in the murine ES cell context (24). To
address this possibility we synthesized the native PB
transposase CDS (hereafter iPB) and a mouse codon
optimized CDS version (hereafter mPB). iPB corresponds
to the original wild-type coding sequence of the PB
transposase, whereas mPB is a synthetic sequence coding
for the same polypeptide as iPB, but where each codon has
been changed for the preferred codon for translation in
mouse cells. Both iPB and mPB contain a Kozak sequence
built around the start methionine codon. Besides this,
potential cryptic splice sites generated during the codon
optimization were detected and avoided in the optimized
sequence.
Expression vectors were assembled by subcloning both
versions of the transposase CDSs into pcDNA3. We
compared their ability to promote transposition of a PB
transposon carrying a promoterless puromycin resistance
cassette from a transfected plasmid vector into the ES cell
genome (Figure 1A). iPB or mPB expression plasmids
were co-electroporated with a transposon donor plasmid
(50-PTK-30) into AB2.2 mouse ES cells and the numbers of
puromycin-resistant colonies were assessed. mPB yielded
considerably more puromycin-resistant colonies than iPB
(Figure 1B).
To address saturation effects the amounts of helper or
donor plasmids were varied while keeping a constant
amount of the respective donor or helper plasmid
(Figure 1C and D). In both series of experiments, mPB
provided higher levels of transposition than iPB through-
out the whole range of amounts of transfected plasmids.
In these experimental conditions we did not observe
overproduction inhibition, a phenomenon described in
certain transposon systems in which transposition rates
decline when the amount of transposase exceeds certain
levels (10,14,18). Interestingly, the levels of transposition
provided by iPB in these series of experiments were far
below those of mPB, especially in Figure 1D, where not
even the highest amount of iPB plasmid is able to match
the levels of transposition obtained by transfection of
the lowest amount of mPB. This is likely due to the
stringent conditions (5 106 cells per transfection and 1 mg
of donor plasmid) of this experiment, aimed at analysing
saturation effects. Additional experiments performed in
less-restrictive conditions showed that increasing amounts
of iPB provided levels of transposition in the same order
of magnitude as those of mPB (Supplementary Figure 2),
indicating that the differences between the performance
of iPB and mPB strongly depend on the experimental
settings. Despite this, we must remark that mPB showed
higher levels of transposition than iPB in all the
conditions tested.
To ascertain if the higher transposition frequency
provided by the optimized sequence was caused by
higher production of transposase we subcloned iPB and
mPB into pcDNA3-Kz-HA, a pcDNA3-based vector
containing a Kozak sequence plus the nucleotide sequence
encoding the hemagglutinin epitope (HA) (Figure 2A),
enabling detection of protein production from HA-iPB
and HA-mPB by Western blot analysis using an anti-HA
antibody. These two plasmids plus an empty pcDNA3-
Kz-HA vector were transfected into COS-7 cells in
triplicate. Analysis of protein lysates using an anti-HA
monoclonal antibody revealed a clear band at the expected
size (68 kDa) in the cells transfected with transposase
expression plasmids, but not in the cells transfected with
the empty vector (Figure 2B). The amount of PB
transposase in the cells transfected with HA-mPB was
considerably and consistently higher than in the cells
transfected with HA-iPB, confirming that higher levels of
transposase production are likely responsible for the
greater transposition activity provided by mPB.
Differential features of the minimum 50 and 30-PB
terminal repeats
The original PB transposon is flanked by 13-bp terminal
inverted repeats and has additional inverted repeats
19-bp long located asymmetrically with respect to the
end of the element (24). These inverted flanking sequences,
although able to permit transposition between different
plasmids in insect cells, were found to be insufficient to
allow transposition from a donor plasmid to genomic
DNA. In fact, additional transposon DNA sequence was
found to be necessary to provide this kind of transposition
(25,26). A 50-terminal repeat (50-TR) of 313 bp and
a 30-terminal repeat (30-TR) of 235 bp have been described
as the minimum PB terminal repeats (25). Combinatorial
experiments performed with the SB transposon have
shown that a configuration containing two ‘left’ terminal
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repeats (or 50-TRs) provides levels of transposition 3 times
higher than the original ‘left’+ ‘right’ combination (11).
In order to study the properties of the 50 and 30-TRs of
the PB element and to explore the possibility of enhancing
the rates of transposition, we subcloned a promoter-less
puromycin resistance cassette between different combina-
tions of minimum 50 and 30-PB terminal repeats
(Figure 3A) (50–50, 50–30, 30–50 and 30–30) and cotransfected
the resulting donor plasmids with the mPB expression
cassette into AB2.2 cells. Only the cells transfected with
the 50–30 and 30–50 configurations yielded significant
numbers of resistant colonies (Figure 3A). These results
indicate that the PB transposon requires one 50 and one
30-terminal repeat in order to achieve transposition.
The number of colonies obtained with the 50–30
transposon was 4.6 times higher than with the 30–50
configuration (Figure 3A). As we had used a promoter-
less selection cassette, one explanation of this observation
is that the promoter sequence predicted in the 50-TR,
which is functional in insect cells, is also active in the
mammalian genome (24,27). To address this possibility,
we subcloned a luciferase expression cassette (Luc2)
downstream of the 50 and 30-PB TRs (Figure 3B) and
assessed luciferase activity in transiently transfected
HeLaS3 cells. The luciferase activity observed with the
50-TR-Luc2 construct was 5 times higher than that
observed in the cells transfected with the 30-TR-Luc2
construct (Figure 3B), indicating that the promoter in the
50-TR repeat is also active in mammalian cells.
Generation of an inducible PB transposase
The success of cancer-gene identification experiments
performed with the SB transposase in mice has been
strongly determined by the levels of transposase activity
(12,13). However, an excess of transposition has been
reported to create undesired genomic rearrangements in
an SB-based system for mouse germline mutagenesis (14).
Thus, the ability to control transposition temporally
would provide an additional advantage to the PB
transposase. To explore the possibility of generating an
inducible transposase we created fusion proteins between
mPB and the modified oestrogen receptor ligand-binding
domain (ERT2), at the N or C terminus of mPB (ERT2-
mPB and mPB-ERT2, respectively) (28) (Figure 4A).
The ERT2 domain provides the possibility of regulating
Figure 1. Comparison of transposase activity of the native and codon optimized piggyBac. (A) Schematic representation of the plasmids used in this
experiment. The donor plasmid, 50-PTK-30, contains the minimal PB terminal repeats (50-TR and 30-TR) flanking a promoter-less puromycin
resistance cassette. CMV, cytomegalovirus promoter; ATG, start codon; pA, bovine growth hormone polyA signal; En2SA, mouse engrailed-2 gene
splice acceptor; IRES, internal ribosomal entry site from encephalomyocarditis virus; puTK, synthetic fusion CDS between the puromycin-
resistance gene and a truncated thymidine kinase gene (21). (B) 2 mg of 50-PTK-30 and 2 mg of the transposase plasmid were co-electroporated into
107AB2.2 mouse ES cells and, after puromycin selection, the numbers or resistant colonies were counted. (C) A fixed amount (1mg) of transposase
plasmid was co-electroporated with increasing amounts (1–40 mg) of 50-PTK-30 into 5 106 AB2.2 ES cells and puromycin-resistant colonies were
counted. (D) A fixed amount (1mg) of 50-PTK-30 transposon plasmid was co-electroporated with increasing amounts (1–40mg) of transposase plasmid
into 5 106 AB2.2 ES cells. Numbers of puromycin-resistant colonies are indicated. n=3, error bars: SEM.
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the activity of a protein by the presence or absence of
4-hydroxytamoxifen (4-OHT). In the absence of 4-OHT a
protein containing the ERT2 domain is sequestered by
heat-shock proteins, preventing it from functioning (29).
In the presence of 4-OHT, the fusion protein is released
and can then play its role (28).
The two key requirements of inducible proteins are high
activity under induced conditions and low/no activity in
the absence of induction. To achieve the maximum activity
and inducibility we evaluated a series of linkers between
mPB and ERT2 of different lengths, charges and flexibil-
ities (Table 1). Most of the fusion proteins appeared to
have reduced activity. The L1 fusions show 100-fold
reductions compared with mPB. The L2 fusions also
exhibited reduced activity although one of them (ERT2-
L2-mPB) was not leaky when not induced. However, the
fusion proteins containing L3 linkers provided high levels
of transposition (Figure 4B). The L3 linker was based on a
sequence which has previously been used between the
GAL4-DNA-binding domain and the native PB transpo-
sase, which resulted in levels of activity of the fusion
protein close to 100% with respect to the wild-type enzyme
(17). The number of colonies obtained in the presence of
4-OHT using mPB-L3-ERT2 was 6 times higher than those
obtained with iPB, though it was less efficient than mPB.
Importantly, the activity was highly 4-OHT-dependent,
since in the absence of 4-OHT transposition was reduced
more than 800-fold to background levels. To our knowl-
edge, mPB-L3-ERT2 is the first PB transposase inducible
by 4-OHT, it provides higher activity than iPB and it shows
undetectable levels of leakiness.
DISCUSSION
The recent availability of DNA transposons which are
active in the mammalian genome has widened the set of
tools to carry out functional genomics and transgenesis.
SB, a transposon reconstructed from inactive sequences
present in salmonid fishes, has already shown great utility,
having being successfully used in cancer-gene identifica-
tion, germline mutagenesis and human cell transgenesis
experiments (3,8,12–14). More recently, PB, an active
transposon from the cabbage looper moth Trichoplusia ni,
has also been shown to work in mammalian cells,
providing transposition levels higher than those displayed
by certain hyperactive SB forms (16–18). These two
transposable elements have distinctive properties, for
instance target sequence preference, which suggests that
they will be used as complementary tools to modify and
study the mammalian genome (8,18,30,31).
We have characterized, optimized and further enhanced
the functionality of the PB transposon/transposase
system. We have synthesized a mouse-codon-optimized
PB transposase CDS, which provides levels of transposi-
tion significantly higher than the native PB transposase
CDS over a wide range of transposon/transposase ratios.
Remarkably, the difference in performance between iPB
and mPB strongly varied with the experimental condi-
tions, although mPB always provided higher levels of
transposition. Notably, overproduction inhibition, the
decrease of transposition produced by excessive trans-
posase previously observed in SB, was not detected for PB
in the experimental conditions we used (10,17,18).
Intriguingly, two previous reports have tried to address
the existence of this phenomenon in PB with disparate
results. On one hand, Wu et al. (17) found overproduction
inhibition of PB in HEK293 cells. On the other hand,
Wilson et al. (18) concluded that PB lacks overproduction
inhibition in HEK293 cells. Interestingly, in the same
study, Wilson et al. transfected equivalent amounts of a
pCMV-based SB12 helper and donor plasmids in
HEK293 cells, and observed the previously reported
overproduction inhibition. Although our results support
the lack of overproduction inhibition in PB, further work
is needed to clarify this issue.
We have also shown that the higher transposition
provided by mPB correlates with increased protein
production. This result highlights the usefulness of
codon optimization to increase protein levels. Besides
this, the availability of two different sequences encoding
PB transposase offers the opportunity to obtain different
levels of protein and transposition activity.
We have analysed the differential properties of the 50
and 30-PB terminal repeats. In contrast with the previous
results obtained with different combinations of the SB
terminal repeats we have only detected transposition
activity when the naturally occurring combination of PB
Figure 2. Levels of protein production provided by the native and
codon optimized piggyBac. (A) Schematic representation of the
plasmids used in this experiment. HA, sequence encoding the
hemagglutinin epitope. (B) pcDNA3-KzHA, HA-iPB or HA-mPB
were transfected into COS-7 cells and the levels of HA-tagged PB
transposase were analysed by Western blot using a specific monoclonal
antibody raised against the HA epitope. The same membrane was
subsequently incubated with a monoclonal anti-actin antibody, as
loading control. Three independent transfections were performed and
analysed per plasmid.
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50-TR and 30-TR was used (11). Interestingly, we obtained
higher numbers of colonies when the resistance cassette
was oriented from the 50-TR to the 30-TR than in the
opposite orientation. In these experiments the transposon
contained a gene-trap selection cassette. As the 50-TR has
been described to contain a promoter active in insect cells,
we hypothesized that the observed differences in colony
numbers could derive from transcriptional activity
from the 50-TR activating the selection cassette (27). In
a promoter analysis experiment using luciferase as a
reporter, we observed that the 50-TR does act as
a promoter which is 5-fold stronger than the 30-TR.
This observation should be considered in the design of
PB-based promoter-less transposons, as the expression
of the promoter-less cassette from the 50-TR repeat
may produce unwanted results. In our view, the
simplest solution would be to rearrange the transposon
so that the 30-TR is upstream of the 50-end of the
promoter-less sequence. Remarkably, recent work has
detected enhancer activity in the 30-TR of the piggyBac
transposon (32). In our opinion, the presence of promoter
and enhancer sequences in the piggyBac 50-TR and 30-TR,
respectively should also be considered in gene-therapy
applications, so as to avoid the negative experiences of
generating activating mutations previously obtained with
retroviruses (33).
Finally, we have engineered an inducible, optimized PB
transposase. We have made and assessed six different
combinations of mPB with ERT2 (28). The six versions
have two different arrangements of ERT2 either at the
C-terminus or at the N-terminus of the PB transposase
coupled with three different linkers (L1, L2 or L3) between
ERT2 and mPB. Four of these fusion proteins show
extremely reduced levels of transposition when compared
to the parental mPB, even in the presence of the inducer,
4-OHT. However, the other two fusion proteins, ERT2-
L3-mPB and mPB-L3-ERT2, produce high levels of
induced transposition. Both of them contain a linker
which was based on an aminoacidic sequence previously
used to fuse the native PB transposase to the GAL4-
DNA-binding domain (17). The length and the net
positive charge of this linker compared with the ones
which were less successful are likely to underlie the
huge differences in activity. Remarkably, mPB-L3-ERT2
yields levels of transposition 6 times higher than iPB in
the presence of 4-OHT, whereas no detectable transposi-
tion was observed without induction. In the absence of
4-OHT the transposition activity provided by mPB-
L3-ERT2 is reduced 800-fold, returning back to the
low experimental noise levels. Thus mPB-L3-ERT2 is not
only an improved version of the PB transposase, but it
can also be temporally regulated. This newly engineered
enzyme will be useful for diverse applications, ranging
from gene therapy, where the possibility of switching
on and off the enzyme would contribute to making it safer,
to forward genetics cancer screens in mice, where the
Figure 3. Analysis of the properties of the piggyBac terminal repeats. (A) Left, schematic representation of transposon plasmids used in this
experiment. Each plasmid contains the same gene trap puromycin resistance cassette flanked by different combinations of 50-TR (blue arrows) and
30-TR (red arrows). Right, 2 mg of transposon plasmids were co-electroporated into 107 AB2.2 mouse ES cells with 2 mg of mPB helper plasmid. The
numbers of puromycin-resistant colonies were counted. (B) Left, schematic representation of the firefly luciferase expression plasmids used in this
experiment. 50-TR-Luc2 contains the minimal left terminal PB repeat followed by the firefly luciferase CDS (Luc2). 30-TR-Luc2 contains the minimal
right terminal PB repeat followed by Luc2. pA, SV40 late polyA region. Right, 50-TR-Luc2 or 30-TR-Luc2 were transfected in HeLaS3 cells together
with pGL4.74, a transfection control plasmid containing the renilla luciferase gene under the thymidine kinase promoter. Twenty-four hours after
transfection firefly and renilla luciferase activities were measured. n=3, error bars: SEM.
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temporal regulation of the transposition activity
would facilitate the adjustment of the dynamics of the
tumourigenic processes to prevent undesired genomic
rearrangements.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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